sa¹ú¼Ê´«Ã½¹ÙÍøÍøÒ³Èë¿Ú

Summary: The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. In a recent Pharmaceutical Technology webcast, Jon Scrafford, Associate Director of Process Engineering at Catalent, and Ryan Minikis, Principal at Arclight  Pharmaceuticals, LLC, explored the use of spray drying to create amorphous solid dispersions (ADSs) and the optimization of process parameters for successful scale-up to commercial manufacture of the final dosage form. Here, Scrafford and Minikis answer several key questions posed by audience members during the Pharmaceutical Technology webcast.